Table 2.

Baseline characteristics of patients who inject opioids admitted with serious injection related infections (SIRI)

	Baseline characteristics
	Referred to EPICC program N= 76	Not Referred to EPICC program N= 244	P value
Demographics
Age (mean)	39.5	39.2	0.789
Female	43 (56.6%)	110 (45.1%)	0.079
African American	43 (56.6%)	96 (39.3%)	0.008
Unhoused	20 (26.3%)	24 (9.8%)	<.001
Substance Use History (all persons in this cohort also used heroin or fentanyl at the time of admission)
Addiction Medicine Consult	69 (90.7%)	82 (33.6%)	<.001
Prior IDU-related infections	2.1	1.9	0.353
Methamphetamine	16 (21.1%)	70 (28.7%)	0.182
Cocaine	27 (35.5%)	57 (23.4%)	0.039
Benzodiazepine	1 (1.3%)	7 (2.9%)	0.417
Comorbidities
Hypertension	10 (13.2%)	29 (11.9%)	0.768
Diabetes Mellitus	3 (3.9%)	20 (8.2%)	0.183
Psychiatric comorbidity	16 (21.1%)	29 (11.9%)	0.053
Hepatitis C infection	66 (86.8%)	147 (60.3%)	<.001
HIV infection	3 (3.9%)	14 (5.7%)	0.531
Type of SIRI*
Infective endocarditis	37 (48.7%)	126 (51.6%)	0.652
Osteomyelitis	25 (32.9%)	77 (31.6%)	0.827
Septic Arthritis	10 (13.2%)	38 (15.6%)	0.602
Epidural Abscess	8 (10.5%)	22 (9.0%)	0.697
Necrotizing Skin and Soft Tissue Infection	10 (13.2%)	25 (10.2%)	0.485
Septic Thrombophlebitis	5 (6.7%)	7 (2.9%)	0.417
Isolated Bacteremia or fungemia	6 (7.9%)	20 (8.2%)	0.933
Causative Organism
Staphylococcus aureus	51 (67.1%)	165 (67.6%)	0.933
Candida species	5 (6.7%)	21 (8.6%)	0.563
Outcomes
90-day Readmission	18 (23.7%)	100 (40.9%)	0.005
Death post-discharge	2 (2.6%)	10 (4.1%)	0.541

IDU, injection drug use; HIV, human immunodeficiency virus; SIRI, serious injection related infection.

^*Patients may have more than one type of infection concurrently